Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indivior Trading Update Reveals Hurdles Suboxone ANDA Filers Are Facing

Executive Summary

Dr Reddy’s Laboratories is agonizingly close to resuming market activities for its generic Suboxone sublingual film product, but recently saw its case to have a mandate confirming the dismissal of a preliminary injunction turned down. In a market update, Suboxone manufacturer Indivior has outlined its plans to combat the imminent threat.
Advertisement

Related Content

Indivior Sets Out Next Steps As It Braces For Suboxone Rivals
US Suboxone Generics Likely To Hit On Monday: Here’s All You Need To Know

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

GB139937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel